Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 74 out of 100. How common it is

Topic: Risk, prevention and care in population studies

Plain-language summary

After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m 2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m 2 at follow-up.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 94 participants. This study followed patients discharged after COVID-19 and found some had ongoing problems with lung diffusion, anxiety or depression, fatigue, and kidney function. It does not address Alzheimer's disease treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., et al. (2021). 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England). https://doi.org/10.1016/s0140-6736(20)32656-8

Vancouver

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England). 2021. doi:10.1016/s0140-6736(20)32656-8. PMID: 33428867.

BibTeX

@article{huang2021-33428867,
  author  = {Huang, C. and Huang, L. and Wang, Y. and Li, X. and Ren, L. and Gu, X. and Kang, L. and Guo, L. and others},
  title   = {{6-month consequences of COVID-19 in patients discharged from hospital: a cohort study}},
  journal = {Lancet (London, England)},
  year    = {2021},
  doi     = {10.1016/s0140-6736(20)32656-8},
  pmid    = {33428867},
  url     = {https://doi.org/10.1016/s0140-6736(20)32656-8}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study followed patients discharged after COVID-19 and found some had ongoing problems with lung diffusion, anxiety or depression, fatigue, and kidney function. It does not address Alzheimer's disease treatment, cure or prevention.

Study details

How this study scored 74/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 2 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 74 of 100.74 of 100 points earned26 not earned

Published in a top-tier journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Lancet (London, England))
Journal's citation record 4 / 4 The Lancet: journal h-index 1,205 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 1 / 4 94 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 4,106 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 586.6 citations a year over 7 year(s) since 2021
Impact for its field and year 6 / 6 Cited 399.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 4 / 4 Cited 755 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Bin Cao: h-index 79 (OpenAlex, whole career)
Institution's track record 1 / 3 Tsinghua University: institution h-index 1,218 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 11 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 33428867)
Free to read 0 / 2 Behind a paywall — scores zero
Total 74 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in How common it is from nearby years

Also tagged “palliative”

858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →